Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $5.7 million.

  • BioXcel Therapeutics' Prepaid Assets rose 2703.73% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 2703.73%. This contributed to the annual value of $5.3 million for FY2024, which is 9015.1% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported Prepaid Assets of $5.7 million as of Q3 2025, which was up 2703.73% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Prepaid Assets ranged from a high of $8.4 million in Q2 2022 and a low of $2.1 million during Q1 2024
  • Its 4-year average for Prepaid Assets is $4.6 million, with a median of $4.7 million in 2025.
  • As far as peak fluctuations go, BioXcel Therapeutics' Prepaid Assets plummeted by 5799.04% in 2024, and later soared by 12524.96% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Prepaid Assets stood at $3.8 million in 2022, then fell by 27.61% to $2.8 million in 2023, then surged by 90.15% to $5.3 million in 2024, then increased by 7.56% to $5.7 million in 2025.
  • Its Prepaid Assets was $5.7 million in Q3 2025, compared to $5.1 million in Q2 2025 and $4.7 million in Q1 2025.